Skip To Main Content
Muloongo Simuzingili on Muck Rack

Muloongo Simuzingili

As seen in: medRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Muloongo

Contact Muloongo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The Health and Economic Impact of the Adult-specific 21-valent (aPCV21) Pneumococcal Conjugate Vaccine vs PCV20 on Invasive Pneumococcal Disease Among Adults Aged 65 years in the United Kingdom: A Modeling Study

|
By Peter Mueller, Muloongo Simuzingili, Ian Matthews
| medRxiv
All authors are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and MSD (UK) Limited, London, UK. aPCV21 was developed by Merck & Co., Inc., Rahway, NJ, USA. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Open in Who Shared View Duplicates (34) Issue with article?

What is driving COVID-19 vaccine hesitancy in Sub-Saharan Africa?

|
By Zelalem Yilma Debebe, Fedja Pivodic, Muloongo Simuzingili, Population GP
| blogs.worldbank.org
As African countries accelerate the deployment of COVID-19 (coronavirus) vaccines, the issue of vaccine hesitancy looms. Globally, there has been a rise in general vaccine hesitancy but especially towards COVID-19 vaccines. In Africa, hesitancy must be viewed in the context of significant vaccine shortage; hesitancy does not explain fully the low vaccination rates in Africa. The slow vaccine rollout on the continent is  due to supply constraints, structural issues, and logistical barriers.
Open in Who Shared Issue with article?
See all 2 articles